Our Services
Medical Information
Helpful Resources
Published on: 3/7/2026
Meningiomas are typically benign, slow-growing tumors that develop from the meninges — the protective layers surrounding the brain and spinal cord — rather than from brain tissue itself. Most are discovered on MRI, and treatment depends on tumor size, location, growth rate, symptoms, and grade. Options range from active monitoring to surgery or radiation therapy.
Key factors to understand include common symptoms (headaches, vision changes, seizures), urgent warning signs, and risk factors such as prior head radiation exposure, hormonal influences, and neurofibromatosis type 2 (NF2). Prognosis varies by tumor grade, and next steps often involve imaging follow-up and specialist consultation.
If you're experiencing symptoms that concern you, taking a free, instant, online symptom check can help you better understand what may be causing them and guide your next steps. It's a quick, private way to organize your symptoms before speaking with a doctor — empowering you to ask the right questions and make informed decisions about your health.
Reviewed for medical accuracy: 07/09/2026
Not seeing your question? No worries.
Submit your own QuestionHearing that you or someone you love may have a meningioma can feel overwhelming. The word "tumor" naturally raises concern. The good news is that most meningiomas are benign (non-cancerous) and often grow slowly. Still, they can cause symptoms and sometimes require treatment.
Let's walk through what a meningioma is, why it develops, what symptoms to watch for, and the medically approved next steps—based on trusted neurological and oncological guidelines.
A meningioma is a tumor that develops from the meninges, the protective layers of tissue that surround your brain and spinal cord. It does not start in the brain itself. Instead, it grows from the membranes covering the brain.
Key facts:
Because they often grow slowly, many meningiomas are discovered incidentally during imaging for another reason.
In most cases, the exact cause of a meningioma is not fully understood. However, several medically recognized risk factors are linked to their development:
Changes in certain genes (especially the NF2 gene) are associated with meningioma formation. People with Neurofibromatosis type 2 (NF2) have a higher risk.
Prior radiation therapy to the head—particularly during childhood—significantly increases risk.
Meningiomas are more common in women and may grow faster during:
This suggests a possible link to estrogen and progesterone receptors.
The risk increases with age, particularly after 40.
Importantly, most people who develop a meningioma have no clear cause. It is not something you did wrong.
Symptoms depend on the tumor's size and location. Some people have no symptoms at all.
When symptoms do occur, they may include:
Because meningiomas grow slowly, symptoms often develop gradually.
If you're experiencing any of these symptoms and want to better understand what might be causing them, Ubie's free AI-powered Benign Tumor of the Nervous System symptom checker can help you assess your situation in just a few minutes and prepare informed questions before your doctor visit.
Doctors typically diagnose a meningioma through imaging studies.
After imaging, doctors classify the tumor by grade:
Knowing the grade helps guide treatment decisions.
Treatment depends on several factors:
Here are the standard approaches used in neurology and oncology.
If the meningioma is:
Your doctor may recommend monitoring with regular MRIs (every 6–12 months at first).
This approach avoids unnecessary surgery while ensuring the tumor does not grow significantly.
Many people live for years with a stable meningioma that never requires treatment.
Surgery is the primary treatment when:
The goal is complete removal, but this depends on location. Tumors near vital nerves or blood vessels may not be fully removable.
Risks vary based on tumor position but may include:
For most Grade I meningiomas that are fully removed, surgery can be curative.
Radiation may be recommended:
Types include:
Radiation can effectively control growth, particularly in smaller tumors.
Malignant (Grade III) meningiomas are rare but require:
Chemotherapy is not commonly effective but may be considered in select cases.
For most people, the outlook is reassuring:
However, atypical and malignant forms require closer follow-up due to higher recurrence risk.
Regular imaging follow-up is critical—even after successful treatment.
Call emergency services or seek urgent care if you experience:
These could signal increased pressure in the brain or bleeding.
If you've been diagnosed, practical steps include:
It can also help to:
Most are not cancer. About 80–90% are benign.
No credible evidence links stress to meningioma formation.
Rarely. Most either remain stable or grow slowly.
No. Many small, symptom-free meningiomas are safely monitored.
A meningioma is a tumor that develops from the protective layers around the brain. Most are benign and slow-growing. While the diagnosis can sound alarming, many cases require only monitoring, and when treatment is needed, outcomes are often very good.
Still, every brain tumor deserves careful evaluation. If you notice persistent neurological symptoms—or have already been diagnosed—your next step should be to speak to a doctor, preferably a neurologist or neurosurgeon. Anything affecting the brain has the potential to become serious, and timely evaluation matters.
If you'd like to quickly assess your symptoms and understand whether they could be related to a Benign Tumor of the Nervous System, Ubie's free AI-powered symptom checker can help you organize your concerns and generate meaningful questions to discuss with your healthcare provider at your next appointment.
You don't need to panic—but you do need accurate information, proper imaging, and professional guidance. With the right care plan, most people with a meningioma go on to live full, meaningful lives.
(References)
* Jaiswal S, Bhalla A, Singh G. *Meningioma: Current concepts and treatment strategies.* Am J Clin Oncol. 2020 Dec;43(12):915-924. doi: 10.1097/COC.0000000000000755. PMID: 32661073.
* Ostrom QT, Diao X, Neff JP. *Pathogenesis and Classification of Meningiomas.* Cancers (Basel). 2022 Feb 7;14(3):805. doi: 10.3390/cancers14030805. PMID: 35140685; PMCID: PMC8834407.
* Li Z, Zhang Z, He Z, Yu Z, Liu P, Guo Z, Cao P. *Management of intracranial meningiomas: An update.* World Neurosurg. 2023 Mar;171:221-229. doi: 10.1016/j.wneu.2022.12.062. Epub 2022 Dec 22. PMID: 36671048.
* Yang M, Lin B, Chen C, Shi X, Hu W, Shi K. *Meningiomas: Diagnostic, therapeutic, and prognostic insights.* Front Oncol. 2023 Feb 1;13:1102987. doi: 10.3389/fonc.2023.1102987. PMID: 36814041; PMCID: PMC9931139.
* Vlasiu AM, Butoescu N, Cioc M, Vlasiu D, Dumitrescu M, Calu V, Popa F, Iancu G, Marinescu T, Vancica L, Manole E. *Meningiomas: An update on clinicopathological features and molecular insights.* Mol Cell Probes. 2023 Oct;71:101957. doi: 10.1016/j.mcpro.2023.101957. Epub 2023 Jul 19. PMID: 37474416.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.